Pr. Dr. Luis Blanco Dávila
Research Professor at Molecular Biology Centre Severo Ochoa from the National Research Council (CSIC) in Madrid. He is an international expert in the molecular biology of polymerases and their biotechnological and biomedical applications. Dr Blanco, has identified and characterised several DNA polymerases including that of phage phi29 (co-inventor in the patent protecting Phi29 DNA polymerase, while he was working at Pr. Dr. Margarita Sala’s lab), as well as Pol lambda and Pol mu. Prof. Blanco has been the leader of different national and international projects in the field of polymerases and has authored more than 100 articles published in international journals. Dr Blanco is founder of X-Pol Biotech, the company that merged with SYGNIS in 2012. Dr. Blanco is one of the key shareholders of SYGNIS.
Pr. Dr. Margarita Salas
Research Professor within the National Research Council Research (CSIC) and ex-President of the Institute of Spain, with over 300 publications in international journals. She was a co-inventor in a biotechnology patent protecting phi29 DNA polymerase and its uses, which raised more than USD$ 10 million in the first year of marketing. Prof Salas is member of European Molecular Biology Organization (EMBO), the American Academy of Arts and Sciences and recipient of the Carlos J. Finlay Award (Unesco). She received the Rey Jaime I Prize for Research and the Santiago Ramon y Cajal National Award for Research, among other accolades. Prof. Salas is one of the key shareholders of SYGNIS.
Mr. Joseph M. Fernández
Mr. Fernandez was one of two co-founders of Invitrogen, Inc., (Currently Life Technologies). He developed and helped launch the company’s first commercial products, as well as all aspects of the company. In 1999, he founded Active Motif, which specializes in novel tools and platform technologies for genomics-driven cell biology and epigenetic pathway elucidation. He is the current chairman of the company.